التفاصيل البيبلوغرافية
| العنوان: |
Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients |
| المؤلفون: |
Thomas Bartl, Jasmine Karacs, Caroline Kreuzinger, Stephanie Pfaffinger, Jonatan Kendler, Cristina Ciocsirescu, Andrea Wolf, Alexander Reinthaller, Elias Meyer, Maximilian Brandstetter, Magdalena Postl, Eva Langthaler, Elena Braicu, Ignace Vergote, Paula Cunnea, Charlie Gourley, Wolfgang Schmitt, Dan Cacsire Castillo-Tong, Christoph Grimm |
| المصدر: |
Cancers; Volume 13; Issue 5; Pages: 1076 |
| بيانات النشر: |
Multidisciplinary Digital Publishing Institute |
| سنة النشر: |
2021 |
| المجموعة: |
MDPI Open Access Publishing |
| مصطلحات موضوعية: |
ovarian cancer, therapy response, platinum-resistant, recurrence, growth rate |
| الوصف: |
This study aimed to assess the predictive value of tumor growth rate estimates based on serial cancer antigen-125 (CA-125) levels on therapy response and survival of patients with recurrent high-grade serous ovarian cancer (HGSOC). In total, 301 consecutive patients with advanced HGSOC (exploratory cohort: n = 155, treated at the Medical University of Vienna; external validation cohort: n = 146, from the Ovarian Cancer Therapy–Innovative Models Prolong Survival (OCTIPS) consortium) were enrolled. Tumor growth estimates were obtained using a validated two-phase equation model involving serial CA-125 levels, and their predictive value with respect to treatment response to the next chemotherapy and the prognostic value with respect to disease-specific survival and overall survival were assessed. Tumor growth estimates were an independent predictor for response to second-line chemotherapy and an independent prognostic factor for second-line chemotherapy use in both univariate and multivariable analyses, outperforming both the predictive (second line: p = 0.003, HR 5.19 [1.73–15.58] vs. p = 0.453, HR 1.95 [0.34–11.17]) and prognostic values (second line: p = 0.042, HR 1.53 [1.02–2.31] vs. p = 0.331, HR 1.39 [0.71–2.27]) of a therapy-free interval (TFI) < 6 months. Tumor growth estimates were a predictive factor for response to third- and fourth-line chemotherapy and a prognostic factor for third- and fourth-line chemotherapy use in the univariate analysis. The CA-125-derived tumor growth rate estimate may be a quantifiable and easily assessable surrogate to TFI in treatment decision making for patients with recurrent HGSOC. |
| نوع الوثيقة: |
text |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| Relation: |
Cancer Therapy; https://dx.doi.org/10.3390/cancers13051076 |
| DOI: |
10.3390/cancers13051076 |
| الاتاحة: |
https://doi.org/10.3390/cancers13051076 |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: |
edsbas.32BC96A6 |
| قاعدة البيانات: |
BASE |